- Home
- RDHL vs BGMS Comparison
RDHL vs BGMS Comparison
Compare RDHL & BGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RDHL | BGMS |
|---|---|---|
| Founded | 2009 | 1996 |
| Country | Israel | Malaysia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 5.0M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | RDHL | BGMS |
|---|---|---|
| Price | $0.85 | $1.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 27.7K | 27.1K |
| Earning Date | 04-09-2026 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $381.91 | $137.21 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $0.73 |
| 52 Week High | $3.31 | $6.70 |
Technical Indicators
Market Signals| Indicator | RDHL | BGMS |
|---|---|---|
| Relative Strength Index (RSI) | 37.02 | 54.32 |
| Support Level | $0.80 | $0.74 |
| Resistance Level | $1.07 | $1.12 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 30.00 | 89.70 |
Price Performance
Historical ComparisonAbout RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About BGMS Bio Green Med Solution Inc.
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.